RBC Capital Remains a Buy on Dyne Therapeutics (DYN)
RBC Capital's Luca Issi has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of $30.00, while the stock closed at $20.90. The analyst consensus for Dyne is Strong Buy, with a price target of $37.11, indicating a potential upside of 77.56%. LifeSci Capital also reiterated a Buy rating with a $40.00 target. Issi has an average return of 6.7% and a 41.16% success rate on his stock recommendations.
In a report released on November 5, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, with a price target of $30.00. The company’s shares closed yesterday at $20.90.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Issi covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Alnylam Pharma, and Ionis Pharmaceuticals. According to TipRanks, Issi has an average return of 6.7% and a 41.16% success rate on recommended stocks.
Dyne Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.11, representing a 77.56% upside. In a report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $40.00 price target.
